Previous close | 193.18 |
Open | 199.18 |
Bid | 201.78 x 100 |
Ask | 202.03 x 100 |
Day's range | 198.97 - 205.75 |
52-week range | 189.44 - 319.76 |
Volume | |
Avg. volume | 1,243,387 |
Market cap | 29.361B |
Beta (5Y monthly) | -0.01 |
PE ratio (TTM) | 25.25 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Shares of the biopharmaceutical company Biogen (BIIB) are on the rise Wednesday, buoyed by the company's first quarter results. The company beat profit expectations, driven by Biogen's cost-cutting initiatives and the boost in sales for its Alzheimer's drug, Leqembi. Yahoo Finance's Anjalee Khemlani breaks down the details of the report. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
On Wednesday, Biogen Inc (NASDAQ:BIIB) reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The company reported sales of $2.29 billion, down 7% year over year and missing the consensus of $2.31 billion. Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Multiple sclerosis drug Tysabri sales were down to $431.3 million from $472.8 million. Also Read: Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analys